Clinical Trials Logo

Clinical Trial Summary

Emergent and infectious diseases are a public health priority on Reunion Island. Amongst public health threats, the infection due to Coxiella burnetii (Q fever) seems to have appeared on Reunion island in 2007 with two hospitalised confirmed cases (one death) and one probable case with a goat farmer.

According to the investigator, the diffusion of C. burnetti is more ancient and such diagnosis have been made in the last 30 years with 80 positive serologies identified between 2005 and 2011.

Considering the high epidemic power of this disease, its often silent clinical expression and its life-threatening condition, the principal investigator wishes to perform a sero-epidemiological study in order to establish or to reject the risk of emergence of Q fever in Reunion island.

The study will be performed on pregnant women because Q fever is responsible for particular complications during pregnancy and because the number of pregnancy followed on Reunion island is stable from one year to the other. The pregnant women population presenting the same exposure criteria as the general population, this population will be used to extrapolate to the general population of the island.


Clinical Trial Description

n/a


Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02898402
Study type Observational
Source Centre Hospitalier Universitaire de la Réunion
Contact
Status Completed
Phase N/A
Start date January 2014
Completion date January 2015

See also
  Status Clinical Trial Phase
Recruiting NCT03334019 - Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France
Active, not recruiting NCT01450501 - Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study) N/A
Recruiting NCT01095328 - A Screening Strategy for Q Fever Among Pregnant Women N/A
Completed NCT02822807 - Q Fever and Auto-immunity N/A
Completed NCT00584454 - Safety Evaluation of a Q-fever Vaccine, NDBR 105 Phase 2
Withdrawn NCT02092142 - Safety and Immunogenicity of Q Fever Vaccine Phase 2
Completed NCT01318356 - The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Phase 4